Basilea Pharmaceutica Completes Key Study on Fosmanogepix in Hepatic Impairment

Basilea Pharmaceutica (CH:BSLN) announced an update on their ongoing clinical study.

In a recent clinical study update, Basilea Pharmaceutica has completed a Phase 1 trial titled A Phase 1, Open-label, Single-dose, Parallel Cohort Study to Assess the Pharmacokinetics and Safety of Fosmanogepix (PF 07842805) in Adult Participants With Varying Degrees of Hepatic Impairment. The study’s primary objective was to evaluate the pharmacokinetics and safety of fosmanogepix in individuals with different levels of liver function, which is crucial for understanding its potential therapeutic use.

The intervention tested was fosmanogepix, a drug administered orally in a single dose. It aims to assess how the drug is processed and eliminated in the body, particularly in patients with hepatic impairment.

This study was designed as an open-label, non-randomized, parallel cohort trial. It involved no masking, and its primary purpose was basic science, focusing on understanding the drug’s behavior in the body.

The study began on October 12, 2022, and was completed with its last update submitted on November 12, 2025. These dates are significant as they mark the progression and completion of the trial, providing a timeline for data analysis and future research directions.

The completion of this study could have positive implications for Basilea Pharmaceutica’s stock performance, as successful results may enhance investor confidence and position the company favorably against competitors in the pharmaceutical industry. The focus on hepatic impairment also highlights a niche market opportunity.

The study is now completed, with further details available on the ClinicalTrials portal.

To learn more about CH:BSLN’s potential, visit the Basilea Pharmaceutica drug pipeline page.